Multivalent entrain-and-amplify immunotherapeutics for...

A - Human Necessities – 61 – K

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

A61K 39/00 (2006.01)

Patent

CA 2612518

The present invention provides a method of treating a cell proliferative disease such as cancer by providing to a subject in need thereof an immunogenic composition comprising plasmid and peptide(s) or analogues thereof. In embodiments of the present invention there is provided methods and compositions for inducing, entraining, and/or amplifying the immune response to MHC class-I restricted epitopes of carcinoma antigens to generate an effective anti-cancer immune response.

La présente invention concerne une méthode destinée au traitement d'une maladie à prolifération cellulaire, telle que le cancer, consistant à fournir à un sujet nécessitant un tel traitement une composition immunogène comprenant un plasmide et un ou plusieurs peptides ou analogues associés. Des modes de réalisation de la présente invention concernent des méthodes et des compositions permettant d'induire, de provoquer et/ou d'amplifier la réponse immunitaire aux épitopes restreints par des molécules du complexe majeur d'histocompatibilité de classe I d'antigènes tumoraux pour produire une réponse immunitaire anticancéreuse efficace.

LandOfFree

Say what you really think

Search LandOfFree.com for Canadian inventors and patents. Rate them and share your experience with other people.

Rating

Multivalent entrain-and-amplify immunotherapeutics for... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Multivalent entrain-and-amplify immunotherapeutics for..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Multivalent entrain-and-amplify immunotherapeutics for... will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFCA-PAI-O-1912020

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.